Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 4/20 | 0.55 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RHOA | P61586 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.53 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.53 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.51 |
| ▸ | CDC25B | P30305 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CDC25A | P30304 | 1/20 | 0.48 |
| ▸ | CDC25C | P30307 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450636 | 0.89 | ALDH1A1 (0.55) | AKR1C3AKR1C2HTTRHOACSNK2A1 | |
| SCHEMBL22801100 | 0.86 | MEN1 (0.55) | AKR1C3AKR1C2HTTALDH1A1MAPT | |
| SCHEMBL29441888 | 0.84 | GSK3B (0.62) | AKR1C3HTTHSD17B10 | |
| SCHEMBL60691 | 0.84 | GSK3B (0.62) | AKR1C3HTTHSD17B10 | |
| SCHEMBL5928256 | 0.83 | RAB9A (0.52) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL2031438 | 0.83 | GSK3B (0.61) | AKR1C3HTTHSD17B10 | |
| SCHEMBL11706688 | 0.83 | GSK3B (0.61) | AKR1C3HTTHSD17B10 | |
| SCHEMBL27820119 | 0.83 | GSK3B (0.61) | AKR1C3HTTHSD17B10 | |
| SCHEMBL27804665 | 0.83 | GSK3B (0.61) | AKR1C3HTTHSD17B10 | |
| SCHEMBL953597 | 0.82 | ALDH1A1 (0.56) | HTTALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| CN-103261156-B | For treating the noval chemical compound of neurodegenerative disease | 鲁汶天主教大学研究开发部 | 2016-12-28 | — | — | CN | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
| CN-103261156-A | New compounds for the treatment of neurodegenerative diseases | LEUVEN K U RES & DEV | 2013-08-21 | — | — | CN | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | AKR1C3 1608/4885AKR1C2 2655/4885HTT 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.